Lurasidon in the treatment of adolescent schizophrenia

Czech version

Authors: Jana Šolcová ¹; Michal Hrdlička ²
Authors‘ workplace: Dětská psychiatrická klinika 2. LF UK a FN Motol a Homolka, Praha ¹; Psychologický ústav FF MU, Brno ²
Published in: Čes. a slov. Psychiat., 122, 2026, No. 1, pp. 25-29.
Category: Case Report
doi: https://doi.org/10.48095/cccsp202523

Overview

Lurasidone is one of the most recently registered antipsychotics on our market, which is indicated for the treatment of schizophrenia not only in adults but also in adolescents. One of its main advantages includes a low risk of cardiometabolic adverse effects. The aim of our case-series is to depict four cases of adolescent patients with schizophrenia who were treated at our department with lurasidone. In three patients, psychotic symptoms disappeared when taking lurasidone, hyperprolactinemia caused by risperidone was normalized, and weight was favorably influenced. In the fourth patient, lurasidone did not prove to be useful.

Keywords:

Schizophrenia – Adolescents – Prolactin – lurasidone – cardiometabolic adverse effects

Sources

1. Clemmensen L, Vernal DL, Steinhausen HC. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry 2012; 12 : 150. doi: 10.1186/1471-244X-12-150.

2. Vancampfort D, Rosenbaum S, Schuch F et al. Cardiorespiratory fitness in severe mental illness: a systematic review and meta-analysis. Sports Med 2017; 47 (2): 343–352. doi: 10.1007/s40279-016-0574-1.

3. Correll CU, Solmi M, Croatto G et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry 2022; 21 (2): 248–271. doi: 10.1002/wps.20994.

4. Ústav zdravotnických informací a statistiky ČR. Aktualizujeme data z databáze zemřelých za rok 2023. [online]. Dostupné z: https: //www.nzip.cz/data/2312–aktualizujeme-data–z-databaze–zemrelych-za–rok -⁠ 2023.

5. Miura I, Horikoshi S, Ichinose M et al. Lurasidone for the treatment of schizophrenia: design, development, and place in therapy. Drug Des Devel Ther 2023; 17 (17): 3023–3031. doi: 10.2147/DDDT.S366769.

6. Stahl SM. Stahl‘s essential psychopharmacology: prescriber’s guide: children and adolescents. Cambridge: Cambridge University Press 2019 : 309.

7. Státní ústav pro kontrolu léčiv. Přehled léčiv. [online]. Dostupné z: https: //prehledy.sukl.cz/prehled_leciv.html#/leciva/0194914.

8. Tarzian M, Soudan M, Alhajji M et al. Lurasidone for treating schizophrenia and bipolar depression: a review of its efficacy. Cureus 2023; 15 (4): e38071. doi: 10.7759/cureus.38071.

9. Lin YW, Chen YB, Hung KC et al. Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose-response meta-analysis. BMJ Ment Health 2024; 27 (1): 301165. doi: 10.1136/bmjment-2024-301165.

10. Švestka J, Mohr P. Nová antipsychotika: lurasidon. Psychiatrie 2011; 15 (3): 160–167.

11. Mohr P, Masopust J. Lurasidon, profil antipsychotika druhé generace. Psychiatrie 2019; 23 (4): 197–204.

12. Mohr P. Vliv lurasidonu na kognitivní funkce u schizofrenie. Čes a slov Psychiat 2020; 116 (6): 302–308.

13. Hubeňák J. Lurasidon v léčbě schizofrenie: kazuistika. Čes a slov Psychiat 2020; 116 (5): 248–250.

14. Ustohal L, Hořínková J. Lurasidon v léčbě pacienta se schizofrenií a metabolickým syndromem. Čes a slov Psychiat 2020; 116 (5): 251–254.

15. Hrdlička M. Atypická antipsychotika v léčbě schizofrenie v adolescenci. Psychiatrie 2021; 25 (2): 83–87.

16. Goldman R, Loebel A, Cucchiaro J et al. Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study. J Child Adolesc Psychopharmacol 2017; 27 (6): 516–525. doi: 10.1089/cap.2016.0189.

17. Correll CU, Tocco M, Hsu J et al. Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve vs. previously treated adolescents with an acute exacerbation of schizophrenia. Eur Psychiatry 2022; 65 (1): 1–35. doi: 10.1192/j.eurpsy.2022.11.

18. Smith RC, Leucht S, Davis JM. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl) 2019; 236 (2): 545–559. doi: 10.1007/s00213-018-5133-z.

19. Salazar de Pablo G, Rodriguez V, Besana F et al. Umbrella review: atlas of meta-analytic evidence of early-onset psychosis. J Am Acad Child Adolesc Psychiatry 2024; 63 : 684–697. doi: 10.1016/j.jaac.2023.10.016.

20. Zhu Y, Li C, Huhn M et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2017; 27 (9): 835–844. doi: 10.1016/j.euroneuro.2017.06.011.

21. Paclt I. Doporučené postupy psychiatrické péče psychiatrické společnosti ČLS JEP. 2022. [online]. Dostupné z: https: //postupy–pece.psychiatrie.cz/specialni–psychiatrie/f2–schizofrenie/schizofrenie–u-deti–a-dospivajicich.

22. Rogdaki M, McCutcheon RA, D’Ambrosio E et al. Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis. Lancet Child Adolesc Health 2024; 8 (7): 510–521. doi: 10.1016/S2352–4642 (24) 00098–00091.

23. Mattingly GW, Haddad PM, Tocco M et al. Switching to lurasidone following 12 months of treatment with risperidone: results of a 6-month, open-label study. BMC Psychiatry 2020; 20 (1): 199. doi: 10.1186/s12888-020-02523-1.

24. Kaguelidou F, Valtuille Z, Durrieu G et al. Weight gain during antipsychotic treatment in children, adolescents, and adults: a disproportionality analysis in the global pharmacovigilance database, vigibase. Drug Saf 2023; 46 (1): 77–85. doi: 10.1007/s40264-022-01252-6.

MUDr. Jana Šolcová

Dětská psychiatrická klinika

2. LF UK a FN Motol a Homolka

V Úvalu 84

150 06 Praha 5

e-mail: jana.solcova@fnmotol.cz